Abstracts tagged "Compliance"

Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 096 • 2020 Pediatric Rheumatology Symposium
Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE
Rotem Semo Oz¹, Linda Wagner-Weiner ², Cuoghi Edens ¹, Grace Cameron ¹ and Melissa Tesher ¹, ¹university of chicago, Chicago, ²University of Chicago, Chicago, Illinois
Background/Purpose: Compared to adults with SLE, young patients with SLE face particular challenges, including more severe disease, more renal involvement and medications side effects like…
Abstract Number: 263 • 2019 ACR/ARP Annual Meeting
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
Laure Gossec¹, Anna Moltó ², Catherine Beauvais ³, Eric Senbel ⁴, René-Marc Flipo ⁵, Sophie Pouplin ⁶, Christophe Richez ⁷, Alain Saraux ⁸, Philippe Gaudin ⁹, Daniel WENDLING ¹⁰ and Maxime Dougados ¹¹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Paris St Antoine University Hospital, Paris, France, ⁴Rheumtologist Private Practice, Marseille, France, ⁵University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France, ⁶Rouen University Hospital, Rouen, France, ⁷Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ⁸CHU de la Cavale-Blanche Brest, Brest, France, ⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ¹⁰Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ¹¹Cochin Hospital, Paris, France
Background/Purpose: In chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis, spondyloarthritis, connective tissue diseases and crystal-induced arthritis, long-term adherence to disease-modifying drugs (DMARDs) is only…
Abstract Number: 1141 • 2019 ACR/ARP Annual Meeting
Racial Disparities in Lupus Medication Adherence
Kai Sun¹, Amanda Eudy ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and is disproportionately more frequent in underrepresented racial minorities. We examined adherence gaps between minority and Caucasian…
Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
René-Marc Flipo¹, Eric Senbel², Sonia Tropé³, Elena Zinovieva⁴, Agnès Courbeyrette⁵ and Hélène Herman-Demars⁴, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology office, Marseille, France, ³149 avenue du Maine, ANDAR, Paris, France, ⁴Medical Department Nordic Pharma, Paris, France, ⁵Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…
Abstract Number: 1243 • 2018 ACR/ARHP Annual Meeting
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Ryan Jessee, Stephanie L. Giattino, Atul Kapila, Katherine Kaufman, Jon Golenbiewski, Brian J. Andonian, David Leverenz and Lisa Criscione-Schreiber, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: In 2016, the American Academy of Ophthalmology published revised guidelines on HCQ dosing, recommending a maximum daily dose of 5mg/kg actual body weight as…
Abstract Number: 2369 • 2018 ACR/ARHP Annual Meeting
Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³, Agnès Courbeyrette⁴ and Hélène Herman-Demars³, ¹Rheumatology, CHU Brest, Brest, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France, ⁴Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens.…
Abstract Number: 2403 • 2018 ACR/ARHP Annual Meeting
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Valérie Devauchelle-Pensec¹, Anne Lohse², Francis Guillemin³, Elisabeth Solau-Gervais⁴, Linda Rossi-Semerano⁵, Agnès Duquesne⁶, Irène Lemelle⁷, Pascal Pillet⁸, Claire Ballot⁹, Laurence Goumy¹⁰, Tu Anh Tran¹¹, Laeticia Sparsa¹², Heloise Reumaux¹³, Anaïs Arbault¹⁴ and Camille Alleyrat¹⁵, ¹Rheumatology, CHU Brest, Brest, France, ²Rheumatology Department, Hopital Nord Franche Comté, Belfort, France, ³Université de Lorraine, EA4360, APEMAC, Nancy, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁶4Department of Nephrology-Rheumatology-Dermatology Pediatric - Rheumatology, Hopital Femme-Mère-Enfant, Bron, France, ⁷Department of pediatric onco-hematology, CHU de Nancy - Hôpitaux de Brabois,, Vandœuvre-Lès-Nancy, France, ⁸Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ⁹Department of Pediatric Rheumatology, Hôpital Jean-Minjoz, Besançon, France, ¹⁰Pediatric, CHU d'Angers, Angers, France, ¹¹Paediatrics, University Hospital, Nîmes, Nîmes, France, ¹²Rheumatology, Hopital Emile Muller, Mulhouse, France, ¹³Pediatric Rheumatology, CHRU Lille, Lille, France, ¹⁴Rheumatology, CHU de Dijon, Dijon, France, ¹⁵134 Inserm CIC-1433 Clinical Epidemiology, CHRU de Nancy, Hôpitaux de Brabois, Nancy, France
Background/Purpose: The therapeutic compliance (TC) is a major issue for the management of Juvenile Idiopathic Arthritis (JIA). The chronic nature of this inflammatory rheumatism requires…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…
Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Elodie de Bock¹, Corrado Bernasconi², Tan P. Pham¹, Ana Maria Rodriguez³, Khaled Sarsour⁴, J. Michael Nebesky² and Christine de la Loge¹, ¹Mapi, Lyon, France, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Patients Like Me (PLM), Cambridge, MA, ⁴Genentech, South San Francisco, CA
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
Abstract Number: 920 • 2017 ACR/ARHP Annual Meeting
Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study
Candace H. Feldman¹, Karen H. Costenbader², Daniel H. Solomon³, S.V. Subramanian⁴ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Among lupus patients, adherence to hydroxychloroquine (HCQ), the backbone of therapy, remains suboptimal. Individual-level factors, including younger age, poverty, and black race, have been…
Abstract Number: 1231 • 2017 ACR/ARHP Annual Meeting
Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence
Ayano Kelly^1,2,3,4, Daniel Sumpton^3,5,6, Clare O'Sullivan², Alexa Meara⁷, Robby Nieuwlaat⁸, Peter Tugwell^9,10,11, Lyn March^12,13,14, Allison Tong^3,6, Karine Toupin-April¹⁵, Francois Nantel¹⁶, B.J.F. Van den Bemt (PharmD, PhD)^17,18, Mary De Vera¹⁹, Vicki Evans²⁰, Willemina Campbell²¹, Peter Wong²², Rebecca Davey²³, Dorcas Beaton^24,25,26, Maria Suarez-Almazor^27,28,29,30, Geraldine Hassett^31,32, Helen I. Keen^33,34,35, Therese Dawson³⁶, Luke Crimston-Smith³⁷ and Kathleen Tymms³⁸, ¹Rheumatology, Canberra Rheumatology, Canberra, Australia, ²Rheumatology, The Canberra Hospital, Canberra, Australia, ³Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, ⁴School of Medicine, Australian National University, Canberra, Australia, ⁵Department of Rheumatology, Concord Hospital, Sydney, Australia, ⁶Sydney School of Public Health, University of Sydney, Sydney, Australia, ⁷Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁸Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, ⁹Center For Global Health, Institute of Population Health, Ottawa, ON, Canada, ¹⁰Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada, ¹¹Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ¹²Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹⁴Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ¹⁵Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁷Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ¹⁸Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁹Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ²⁰Clear Vision Consulting, Canberra, Australia, ²¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²²Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ²³Arthritis ACT, Canberra, Australia, ²⁴Research, Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada, ²⁵Scientist, Institute for Work & Health, Toronto, ON, Canada, ²⁶Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ²⁷GIM, AT & EC, UT MD Anderson Cancer Center, Houston, TX, ²⁸Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²⁹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,, The University of Texas MD Anderson Cancer Center, Houston, TX, ³⁰The University of Texas MD Anderson Cancer Center, Houston, TX, ³¹Rheumatology, Liverpool Hospital, Sydney, Australia, ³²Ingham Institute, Sydney, Australia, ³³Rheumatology, Royal Perth Hospital, Perth, Australia, ³⁴Leeds, Leeds, United Kingdom, ³⁵School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, ³⁶Rheumatology, Lord Street Specialist Centre, Port Macquarie, Australia, ³⁷Australian National University, Canberra, Australia, ³⁸ANU, Canberra, Australia
Background/Purpose: Poor medication adherence attenuates optimal clinical benefits and reduces the overall effectiveness of health systems. A large number of interventions targeting medication adherence have…
Abstract Number: 1244 • 2017 ACR/ARHP Annual Meeting
Are Chinese-American Rheumatology Patients Who Use Traditional Chinese Medicine Less Adherent to Prescribed Western Medications?
Kai Sun¹, Jackie Szymonifka², Henghe Tian³, Ya Ju Chang⁴, Jennifer Leng⁵ and Lisa A. Mandl⁶, ¹Hospital for Special Surgery/Weill Cornell medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Mount Sinai Beth Israel, New York, NY, ⁵Immigrant Health and Cancer Disparities laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, ⁶Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: High adherence is crucial for the management of rheumatic diseases. Nonadherence is more common among immigrants and minorities and may contribute to known outcome…
Abstract Number: 1262 • 2017 ACR/ARHP Annual Meeting
Stability of Two Short Medication Adherence Questionnaires over Time for Follow-up in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Charles H. Goldsmith², Imy Chiu³, Anna Gutlin³, Sharron Sandhu⁴ and Mary J. Bell⁵, ¹Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²Simon Fraser University, Vancouver, BC, Canada, ³Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for better monitoring…
Abstract Number: 1601 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Alexandra Perel-Winkler¹, Kayla Neville¹, James Miceli¹, Samantha Nguyen¹, Miya Okado¹, Laura Geraldino-Pardilla¹, Teja Kapoor¹, Jon T. Giles² and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Non-adherence to medication has been shown to impact mortality, morbidity, and health care utilization in SLE and ranges from 40-80% depending on the methods…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].